We conducted a secondary data analysis using data from
prospective, hospital based operations research in Egypt
in 2006. The objective of the original operations research
was to compare the current protocol for the AMTSL
with the use of 600μg of misoprostol. The conclusion
was that misoprostol should be considered for inclusion
in the AMTSL protocol where oxytocin and or ergometrine are not consistently andappropriately used during
the 3
rd
stage of labor. The original study was analyzed as
a pre-/post-intervention study. In the current study, we
analyzed all women who experienced PPH as‘cases’ and
all women who did not experience PPH as‘controls.’
Details on design data, collection, and results of the original study are reported elsewhere [29]. Over a 6-month
period, 2532 pregnant women were recruited into the
study from three university hospitals. Inclusion criteria
were: anticipated singleton vaginal delivery, gestational
age greater than 36 weeks, and ability to give informed
consent. Women who delivered by cesarean section or
women with missing information on delivery type were
excluded from this analysis, leaving a total of 2510 women